Download Reference Coordinates Table 29B

LIST OF PUBLICATIONS REFERRED TO
IN THE 23RD EDITION (2012 – 2013) OF THE BELGIUM – LUXEMBOURG VERSION
OF THE SANFORDGUIDE TO ANTIMICROBIAL THERAPY
TABLE 29B
INFECTION AND TRANSPLANTATION: PREVENTION OF OPPORTUNISTIC INFECTIONS
IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
OR SOLID ORGAN TRANSPLANT (SOT) RECIPIENTS
29B.1 Cadena J, Levine DJ, Angel LF, Maxwell PR, Brady R, Sanchez JF, Michalek JE, Levine SM, Restrepo MI. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009;9:2085-91.
29B.2 Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006;8:213-8.
29B.3 Drew RH, Dodds Ashley E, Benjamin DK, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation 2004;77:232-7.
29B.4 Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, Baden LR. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections
following lung transplantation: a retrospective study. Transpl Infect Dis 2007;9:121-5.
29B.5 Salman N, Törün SH, Budan B, Somer A. Invasive aspergillosis in hematopoietic stem cell and solid
organ transplantation. Expert Rev Anti Infect Ther 2011;9:307-15.
29B.6 Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de
Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for
prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347.
29B.7 Ben-Ami R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell
transplantation: current trends and new challenges. Curr Opin Infect Dis 2009;22:376-84.
29B.8 Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008;61:
734-42.
29B.9 Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo
MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern Med 2003;
138:705-13.
29B.10 Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68.
29B.11 Narimatsu H, Kami M. Management of fungal infections following allogeneic stem cell transplantation.
Expert Rev Anti Infect Ther 2008;6:373-84.
29B.12 Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L.
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic
stem cell transplants. Blood 2004;103:1527-33.
29B.13 Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, Wagener MM, Kusne
S, Singh N. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case controlled study. Transplantation 2003;75:2023-9.
29B.14 Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver
transplant patients: a systematic review and meta-analysis. Liver Transpl 2006;12:850-8.
29B.15 Şensoy G, Belet N. Invasive Candida infections in solid organ transplant recipient children. Expert
Rev Anti Infect Ther 2011;9:317-24.
29B.16 Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Curr Opin Infect Dis 2008;21:409-14.
29B.17 Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L.
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic
stem cell transplants. Blood 2004;103:1527-33.
29B.16 Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68.
29B.18 Narimatsu H, Kami M. Management of fungal infections following allogeneic stem cell transplantation.
Expert Rev Anti Infect Ther 2008;6:373-84.
29B.20 Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo
MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern Med 2003;
138:705-13.
29B.21 Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40.
29B.22 Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of
CMV infection in organ transplant recipients. Clin Infect Dis 2008;47:296-7.
29B.23 Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR. Delayed-onset
primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6.
29B.24 Torres-Madriz G, Boucher HW. Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008;47:702-11.
29B.25 Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF Workshop, 2007. Herpes 2008;15:412.
29B.26 Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC.
Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ
transplants: a systematic review of randomised controlled trials. Lancet 2005;365: 2105-15.
29B.27 Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-Analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;
143:870-80.
29B.28 Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus
workshop on cytomegalovirus management in solid ogan transplantation. Final report. Am J
Transplant 2005;5:218-27.
29B.29 Singh N. Late onset cytomegalovirus disease as a significant complication in solid organ transplant
29B.30
29B.31
29B.32
29B.33
29B.34
29B.35
29B.36
29B.37
29B.38
29B.39
29B.40
29B.41
29B.42
29B.43
29B.44
29B.45
29B.46
29B.47
29B.48
29B.49
29B.50
29B.51
29B.52
29B.53
29B.54
29B.55
29B.56
29B.57
29B.58
29B.59
29B.60
29B.61
recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005;
40:704-8.
Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005;40:709-12.
Mwintshi K, Brennan DC. Prevention and management of cytomegalovirus infection in solid-organ
transplantation. Expert Rev Anti Infect Ther 2007;5:295-304.
Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with
ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006:
43:869-80.
Meylan PR, Pascual M. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know. Clin Infect Dis 2006;43:881-3.
Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology 2011;2011:305-9.
Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy
for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence
of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009;63:600-8.
Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stemcell transplantation.
Transpl Infect Dis 2007;9:102-7.
Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68.
Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002;35:999-1004.
Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic
stem cell transplants. Clin Microbiol Rev 2003;16:647-57.
Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of
ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007;45:
439-47.
Avery RK. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma
of donor-positive/recipient-negative serostatus. Clin Infect Dis 2007;45:448-9.
Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention
strategies after liver transplantation. Am J Transplant 2008;8:158-61.
Egli A, Bergamin O, Müllhaupt B, Seebach JD, Mueller NJ, Hirsch HH. Cytomegalovirus-associated
chorioretinitis after liver transplantation: case report and review of the literature. Transpl Infect Dis
2008;10:27-43.
Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir
administered as pre-emptive therapy for cytomegalovirus disease in liver transplant recipients: impact
on viral load and late onset cytomegalovirus disease. Transplantation 2005;79:85-90.
Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae and mortality) in liver
transplant recipients with the use of pre-emptive therapy for 13 years. Transplantation 2005;79:
1428-34.
Zamora MR, Davis RD, Leonard C (CMV Advisory Board Expert Committee). Management of cytomegalovirus infection in lung transplant recipients: evidence based recommendations. Transplantation 2005;80:157-63.
Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison. Meta-analysis. Clin
Infect Dis 2011;52:313-21.
Avery RK. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less
really more? Clin Infect Dis 2011;52:322-4.
Pietersma FL, van Dorp S, Minnema MC, Kuball J, Meijer E, Schuurman R, van Baarle D. Influence
of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell
transplantation in CMV-seropositive recipients. Clin Infect Dis 2011;52:e144-8.
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients.
Infect Dis Clin North Am 2010;24:319-37.
Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S (French CMV
Resistance Survey Study Group). Drug-resistant cytomegalovirus in transplant recipients: a French
cohort study. J Antimicrob Chemother 2010;65:2628-40.
Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A (Transplantation Society International CMV Consensus Group). International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95.
Reischig T. Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 2010;8:903-10.
Manuel O, Perrottet N, Pascual M. Valganciclovir to prevent or treat cytomegalovirus disease in organ
transplantation. Expert Rev Anti Infect Ther 2011;9:955-65.
Reischig T. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy. Expert Rev Anti Infect Ther 2012;10:51-61.
van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir
as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous
ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006;37:
693-8.
Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields KK, Goldstein S. Valganciclovir is
safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell
transplantation. Bone Marrow Transplant 2006;37:851-6.
Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007;
14(suppl. 1):37-44.
Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24
(suppl. 1):55-62.
Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem
cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52.
Moses SE, Lim ZY, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and mana-
29B.62
29B.63
29B.64
29B.65
29B.66
29B.67
29B.68
29B.69
29B.70
29B.71
29B.72
29B.73
29B.74
29B.75
29B.76
29B.77
29B.78
29B.79
29B.80
29B.81
29B.82
29B.83
29B.84
29B.85
29B.86
29B.87
29B.88
29B.89
29B.90
29B.91
29B.92
29B.93
29B.94
29B.95
gement in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2011;9:891-9.
Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R,
Anschuetz G, Bell S, Condreay L, Brown N (Lamivudine North American Transplant Group). A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32.
Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, Bassendine M, O'Grady
JG, Portmann BC, Anschuetz G, Barrett CA, Williams R, Atkins M. Randomized trial of lamivudine
versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94.
Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. J Am Med Assoc 2006;296:184350.
Biggins SW, Terrault NA. Management of recurrent hepatitis C in liver transplant recipients. Infect
Dis Clin North Am 2006;20:155-74.
Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J
Transplant 2007;7:741-7.
Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after
hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;193:266-70.
Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young JA, Kukreja M, Gress R, Tomblyn M,
Boeckh M. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011;17:664-73.
Rodriguez M, Sifri CD, Fishman JA. Failure of low dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004;38:e76-8.
Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004;4(suppl. 10):135-41.
Derouin F, Pelloux H (ESCMID Study Group on Clinical Parasitology). Prevention of toxoplasmosis in
transplant patients. Clin Microbiol Infect 2008;14:1089-101.
Fernàndez-Sabé N, Cervera C, Fariñas MC, Bodro M, Muñoz P, Gurguí M, Torre-Cisneros J, MartínDávila P, Noblejas A, Len O, García-Reyne A, Del Pozo JL, Carratalà J. Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis 2012;54:355-61.
Kun H, Moore A, Mascola L, Steurer F, Lawrence G, Kubak B, Radhakrishna S, Leiby D, Herron R,
Mone T, Hunter R, Kuehnert M (Chagas Disease in Transplant Recipients Investigation Team).
Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009;48:1534-40.
Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, Morris MI, Nowicki M,
Wright C, Ison MG. Screening and treatment of Chagas disease in organ transplant recipients in the
United States: recommendations from the Chagas in Transplant Working Group. Am J Transplant
2011;11:672-80.
Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella
H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. Evaluation and treatment
of Chagas disease in the United States: a systematic review. J Am Med Assoc 2007;298:2171-81.
Altclas JD, Barcan L, Nagel C, Lattes R, Riarte A. Organ transplantation and Chagas disease. J Am
Med Assoc 2008;299:1134-5.
Bestetti RB, Theodoropoulos TA. A systematic review of studies on heart transplantation for patients
with end-stage Chagas’ heart disease. J Cardiac Fail 2009;15:249-55.
Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by
Coccidioides species. Curr Opin Infect Dis 2008;21:415-20.
Soave R. Prophylaxis strategies for solid organ transplantation. Clin Infect Dis 2001;33(suppl. 1):
S26-31.
Parasitic infections. Am J Transplant 2004;4(suppl. 10):142-55.
Fungal infections. Am J Transplant 2004;4(suppl. 10):110-34.
Cytomegalovirus. Am J Transplant 2004;4(suppl. 10):51-8.
Avery RK. Prophylactic strategies before solid organ transplantation. Curr Opin Infect Dis 2004;17:
353-6.
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14.
Martín-Dávila P, Fortún J, López-Vélez R, Norman F, Montes de Oca M, Zamarrón P, González MI,
Moreno A, Pumarola T, Garrido G, Candela A, Moreno S. Transmission of tropical and geographically
restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008;21:60-96.
Sun HY, Singh N. Pharmacotherapy of post-transplant viral infections. Expert Opin Pharmacother
2008;9:2409-21.
Bouza E, Loeches B, Muñoz P. Fever of unknown origin in solid organ transplant recipients. Infect
Dis Clin North Am 2007;21:1033-54.
Hanson K, Alexander B. Strategies for the prevention of infection after solid organ transplantation.
Expert Rev Anti Infect Ther 2006;4:837-52.
Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis
2007;44:857-66.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh
MJ. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238.
Castagnola, Faraci M. Management of bacteremia in patients undergoing hematopoietic stem cell
transplantation. Expert Rev Anti Infect Ther 2009;7:607-21.
Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients
receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2010;45:662-7.
Shiley K, Blumberg E. Herpes viruses in transplant recipients: HSV, VZV, human herpes viruses, and
EBV. Hematol Oncol Clin North Am 2011;25:171-91.
San-Juan R, Aguado JM, Lumbreras C, Fortun J, Len O, Muñoz P, Montejo M, Moreno A, Cordero E,
Blanes M, Ramos A, de la Torre-Cisneros J, Lopez-Medrano F, Carratala J, Moreno E (RESITRAREIPI Network, Spain). Universal prophylaxis with fluconazole for the prevention of early invasive
fungal infection in low-risk liver transplant recipients. Transplantation 2011;92:346-50.
Almyroudis NG, Segal BH. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010;8:
1451-66.
29B.96
Brizendine KD, Vishin S, Baddley JW. Antifungal prophyalxis in solid organ transplant recipients.
Expert Rev Anti Infect Ther 2011;9:571-81.
Razonable RR. Management of viral infections in solid organ transplant recipients. Expert Rev Anti
Infect Ther 2011;9:685-700.
29B.98 Engelhard D, Akova M, Boeckh MJ, Freifeld A, Sepkowitz K, Viscoli C, Wade J, Raad I. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:46770.
29B.99 Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, McDonald GB, Hirsch H. Viral
disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:47182.
29B.100 Marr KA, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, Steinbach W, Wingard JR, Nucci M.
Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;
44:483-7.
29B.101 Angarone M, Ison MG. Prevention and early treatment of opportunistic viral infections in patients with
leukemia and allogeneic stem cell transplantation recipients. J Natl Compr Canc Netw 2008;6:191201.
29B.97